Cookies on VetMed Resource

Like most websites we use cookies. This is to ensure that we give you the best experience possible.

 

Continuing to use www.cabi.org  means you agree to our use of cookies. If you would like to, you can learn more about the cookies we use.

VetMed Resource

Veterinary information to support practice, based on evidence and continuing education

Sign up to receive our Veterinary & Animal Sciences e-newsletter, book alerts and offers direct to your inbox.

Results per page:

Search results

Abstract

Background: Results of ACTH stimulation test (ACTHst), pre- and post-trilostane serum cortisol concentrations (SCCs), urine concentration (urine-specific gravity [USG]), and urine cortisol : creatinine ratios (UCCRs) are common variables used to monitor trilostane treatment of dogs with...

Author(s)
Bermejo, C. A.; Alenza, D. P.; José, P. G. S.; Llauet, L.; Pérez-López, L.; Melián, C.; Feldman, E. C.
Publisher
Wiley, Boston, USA
Citation
Journal of Veterinary Internal Medicine, 2020, 34, 4, pp 1413-1422
Abstract

Background: Glucocorticoids influence the synthesis and metabolism of catecholamines (epinephrine and norepinephrine) and metanephrines (metanephrine and normetanephrine). The aim of this study was to measure urinary catecholamines and metanephrines in dogs with hypercortisolism before and during ...

Author(s)
Sieber-Ruckstuhl, N.; Salesov, E.; Quante, S.; Riond, B.; Rentsch, K.; Hofmann-Lehmann, R.; Reusch, C.; Boretti, F.
Publisher
BioMed Central Ltd, London, UK
Citation
BMC Veterinary Research, 2017, 13, 279, pp (4 September 2017)
Abstract

Background: The ideal method for monitoring trilostane therapy in dogs with hypercortisolism is still open to debate. Recently, determination of the pre-trilostane (prepill) cortisol concentration has been proposed to be more repeatable than either post-trilostane or post-ACTH cortisol. The aim of...

Author(s)
Boretti, F.; Musella, C.; Burkhardt, W.; Kuemmerle-Fraune, C.; Riond, B.; Reusch, C.; Sieber-Ruckstuhl, N.
Publisher
BioMed Central Ltd, London, UK
Citation
BMC Veterinary Research, 2018, 14, 417, pp (27 December 2018)
Abstract

It is recommended that trilostane therapy of canine hyperadrenocorticism is monitored using an ACTH stimulation test, however this has never been validated. Three Cortisol concentrations (pre-trilostane, 3-hour posttrilostane and 1-hour post-ACTH stimulation) were compared to a clinical score...

Author(s)
Macfarlane, L.; Parkin, T.; Ramsey, I.
Publisher
BMJ Publishing Group, London, UK
Citation
Veterinary Record, 2016, 179, 23, pp 597
Abstract

Many articles published in the past few years have contributed to a better understanding of the use of trilostane in dogs. Trilostane is a competitive inhibitor of 3β-hydroxysteroid dehydrogenase, the enzyme essential for synthesis of Cortisol and all other steroids. Trilostane is reported to be...

Author(s)
Lemetayer, J.; Blois, S.
Publisher
Canadian Veterinary Medical Association, Ottawa, Canada
Citation
Canadian Veterinary Journal, 2018, 59, 4, pp 397-407
Abstract

Background: A high prevalence of cholestatic disease, including gallbladder mucocele (GBM), has been reported in dogs with naturally occurring pituitary-dependent hyperadrenocorticism (PDH). Hypothesis/Objectives Differences exist in the clinical features of dogs with PDH and concurrent cholestatic ...

Author(s)
Kim, K. H.; Han, S. M.; Jeon, K. O.; Kim, H. T.; Li, Q.; Ryu, M. O.; Song, W. J.; Park, S. C.; Youn, H. Y.
Publisher
Wiley, Boston, USA
Citation
Journal of Veterinary Internal Medicine, 2017, 31, 2, pp 335-342
Abstract

Metastatic pituitary carcinoma and central vestibular syndrome originating in the thalamus are not common disorders in dogs. An 11-year-old Maltese dog with pituitary-dependent hypercortisolism presented signs of central vestibular dysfunction after trilostane treatment. Interestingly, the patient...

Author(s)
Arias, E. A. S.; Trigo, R. H.; Alvarez, C. M. G.; Castillo, V. A.
Publisher
BMJ Publishing Group, London, UK
Citation
Veterinary Record Case Reports, 2020, 8, 1,
Abstract

The aim of this study was to describe the incidence and permanence of hypoadrenocorticism associated with trilostane treatment and to assess potential risk factors for hypoadrenocorticism. A retrospective cohort study was conducted using case records for 156 dogs treated with trilostane after a...

Author(s)
King, J. B.; Morton, J. M.
Publisher
Elsevier Ltd, Oxford, UK
Citation
Veterinary Journal, 2017, 230, pp 24-29
Abstract

Background: Lowering the cosyntropin dose needed for ACTH stimulation would make the test more economical. Objectives: To compare the cortisol response to 1 and 5 µg/kg cosyntropin IV in dogs being screened for hyperadrenocorticism (HAC) and in dogs receiving trilostane or mitotane for...

Author(s)
Aldridge, C.; Behrend, E. N.; Kemppainen, R. J.; Lee-Fowler, T. M.; Martin, L. G.; Ward, C. R.; Bruyette, D.; Pannu, J.; Gaillard, P.; Lee, H. P.
Publisher
Wiley-Blackwell, Boston, USA
Citation
Journal of Veterinary Internal Medicine, 2016, 30, 5, pp 1637-1641
Abstract

Trilostane, a competitive inhibitor of 3β-hydroxysteroid dehydrogenase, is often used to treat canine hyperadrenocorticism. In some species, trilostane has been shown to have additional effects on steroid biosynthesis, and it has been postulated that trilostane might have effects on...

Author(s)
Teshima, T.; Matsumoto, H.; Kumagai, T.; Kurano, M.; Koyama, H.
Publisher
Elsevier Ltd, Oxford, UK
Citation
Veterinary Journal, 2014, 200, 3, pp 452-455

Refine Results

Sort Order
Author
Geographical Location
Item Type
Language
Organisms
Subject Topics